Form 4: Madrigal Pharmaceuticals Director Exercises Options and Sells Shares Under Pre-Arranged Plan

Paul A. Friedman, a Director at Madrigal Pharmaceuticals, exercised stock options and subsequently sold 28,876 shares of common stock for approximately $10.2 million under a Rule 10b5-1 trading plan.

Summary

• Director Paul A. Friedman exercised stock options for a total of 28,876 shares of Madrigal Pharmaceuticals common stock at an exercise price of $9.45 per share on July 16 and July 17, 2025.
• Concurrently with the option exercises, Friedman sold all 28,876 shares acquired on the same dates.
• On July 16, 2025, 26,176 shares were sold at weighted average prices ranging from $350.1669 to $356.6177, generating approximately $9,250,741.12 in proceeds.
• On July 17, 2025, 2,700 shares were sold at weighted average prices ranging from $350.1015 to $351.5686, generating approximately $946,301.02 in proceeds.
• The total estimated proceeds from these sales amount to approximately $10,197,042.14.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025.
• Following these transactions, Paul A. Friedman directly holds 187,164 shares of common stock and indirectly holds 655,540 shares through SQN LLC.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive from the perspective of the insider, who realized significant profits from exercising options and selling shares. For the company, it's neutral as it's a pre-planned transaction, but insider selling can sometimes be viewed with slight caution by the market, though mitigated by the 10b5-1 plan.

Positives

• The director realized significant gains by exercising stock options at a low price ($9.45 per share) and selling the shares at substantially higher market prices (ranging from $350.00 to $357.00 per share).
• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned liquidity event rather than a reaction to new, negative information about the company.

Negatives

• The director's net direct beneficial ownership of common stock did not increase as the shares acquired through option exercise were immediately sold.
• Insider selling, even under a 10b5-1 plan, can sometimes be perceived with slight caution by investors as it reduces the insider's direct stake in the company.

Future Outlook

NA

Industry Context

This Form 4 filing details routine insider transactions for a director at a pharmaceutical company. Such transactions, particularly when executed under a Rule 10b5-1 plan, are common for executives and directors managing their personal portfolios and compensation, and do not inherently reflect broader industry trends or specific company performance beyond the stock price at the time of sale.

Related Party Transactions

• Paul A. Friedman indirectly holds 655,540 shares through SQN LLC, where he and his spouse are managing members. He disclaims beneficial ownership except to the extent of his pecuniary interest.

Stakeholder Impact

• Shareholders: The sale of shares by a director, even under a 10b5-1 plan, could be interpreted by some shareholders as a reduction in insider alignment, though the pre-planned nature mitigates negative implications.

Key Dates

Keywords

Madrigal Pharmaceuticals, MDGL, SEC Form 4, Insider Trading, Stock Option Exercise, Share Sale, Rule 10b5-1 Plan, Director Transactions, Beneficial Ownership